18 March 2010

Two diabetes drugs fail to help high-risk patients

The Novartis diabetes drug Starlix failed to reduce progression to the disease or cut down on serious heart problems in patients at high risk for both diabetes and heart disease, according to a large study released on Sunday.

This article has not necessarily been edited by Health24.

The failure of Starlix to provide benefit to these patients and lack of heart impact by Diovan came as a surprise to researchers."Most experts believed that nateglinide would prevent diabetes and that valsartan would reduce cardiovascular events in this population," said Dr. Robert Califf, the study's lead investigator."Interestingly, with respect to nateglinide, we found the opposite," Cardiff said.Starlix works by minimizing spikes in blood sugar after meals by stimulating the pancreas to produce more insulin, leading researchers to believe it might slow progression to diabetes by restoring a more normal insulin response.


Read Health24’s Comments Policy

Comment on this story
Comments have been closed for this article.

Ask the Expert

Diabetes expert

Dr. May currently works as a fulltime endocrinologist and has been in private practice since 2004. He has a variety of interests, predominantly obesity and diabetes, but also sees patients with osteoporosis, thyroid disorders, men's health disorders, pituitary and adrenal disorders, polycystic ovaries, and disorders of growth. He is a leading member of several obesity and diabetes societies and runs a trial centre for new drugs.

Still have a question?

Get free advice from our panel of experts

The information provided does not constitute a diagnosis of your condition. You should consult a medical practitioner or other appropriate health care professional for a physical exmanication, diagnosis and formal advice. Health24 and the expert accept no responsibility or liability for any damage or personal harm you may suffer resulting from making use of this content.

* You must accept our condition

Forum Rules